We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 117

News Bytes - April 18, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

The U.S. Department of Commerce announces the winners of the U.S. Patent and Trademark Office's Patents for Humanity pilot program. The awards


SCOTUS hears arguments on patentability of human genes
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

The U.S. Supreme Court (SCOTUS) heard arguments on Monday specifically addressing whether "human genes are patentable." Ass'n for Molecular Pathology


Myriad Genetics, gene by gene settle BRCA infringement dispute
  • Shook Hardy & Bacon LLP
  • USA
  • February 13 2014

According to a joint news release, Myriad Genetics, Inc. and other owners of the BRCA1 and BRCA2 gene patents have settled patent infringe- ment


News Bytes - June 6, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • June 6 2013

The U.S. Patent and Trademark Office creates the After Final Consideration Pilot Program 2.0 which modifies and extends a program designed to


Exhaustion doctrine applied to method patent
  • Shook Hardy & Bacon LLP
  • USA
  • November 21 2013

A divided Federal Circuit Court of Appeals panel has determined that a method patent holder that gave away 60 percent of the blood-glucose testing


Ambry Genetics countersues Myriad Genetics in genetic patent infringement suit
  • Shook Hardy & Bacon LLP
  • USA
  • August 15 2013

Responding to the patent infringement claims asserted against it by Myriad Genetics, Ambry Genetics Corp. denies that the 15 patents at issue were


Court denies Myriad’s request to enjoin sale of rival BRCA1BRCA2 tests
  • Shook Hardy & Bacon LLP
  • USA
  • March 20 2014

A federal court in Utah has denied the request for a preliminary injunc- tion filed by Myriad Genetics against a rival company that offered tests


Indian Supreme Court rules Novartis cancer drug change not patentable
  • Shook Hardy & Bacon LLP
  • India
  • April 4 2013

The Supreme Court of India has rejected the patent application filed by Novartis AG for a beta crystalline form of its cancer drug Gleevec, also


News Bytes - April 4, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • April 4 2013

The U.S. Food and Drug Administration (FDA) issues draft guidance titled "Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors


FTC issues report on “pay-for-delay” agreements
  • Shook Hardy & Bacon LLP
  • USA
  • January 24 2013

The U.S. Federal Trade Commission (FTC) has published an overview of fiscal year 2012 agreements resolving "patent disputes between a brand and a